FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 506 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Asciminib NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable for Reaching High-Risk and Underserved Populations ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at Work (PSR) as a Critical Opportunity to Protect the Wellbeing of the Cancer... MOST POPULAR Medicare Open Enrollment is Almost Here-What You Need to Know for... October 13, 2020 For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... August 29, 2022 FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... September 15, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab April 10, 2025 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Inavolisib Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear...
